secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2026-06-11T12:02:57+00:00
Accession:  0001619856-26-000043
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou reports vispa-cel 82% ORR, 17.1mo mPFS in 2L LBCL; CB-011 83% CR rate in MM
--------------------------------------------------------------------------------

- Vispa-cel in 27 optimized 2L LBCL patients: 82% ORR, 67% CR, 17.1 months median PFS.
- Vispa-cel safety: no GvHD, no grade 3+ ICANS; one grade 3+ CRS; one related death (IEC-HS).
- FDA aligned on ANTLER-3 phase 3 design for vispa-cel; ~250 CD19-naïve 2L LBCL patients, primary endpoint PFS.
- CB-011 in 12 BCMA-naïve r/r MM patients at RDE: 92% ORR, 83% ≥CR, 91% MRD negativity, 50% in ≥CR at 15 months.
- CB-011 case study: patient after 8 prior lines (incl. autologous CAR-T) achieved CR; dose expansion data expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985626000043/0001619856-26-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985626000043/crbu-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001619856-26-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer